Chemotherapy-Induced Nausea and Vomiting in Gastrointestinal Cancer Patients: Do We Need to Revisit Guidelines?

Abstract

Purpose The objective of this study was to assess the proportion of patients developing chemotherapy-induced nausea and vomiting (CINV) after receiving chemotherapy for gastrointestinal (GI) cancers, despite receiving antiemetic prophylaxis (AEP) as per the standard guidelines.

Patients and Methods Between April 2019 and March 2020, all patients planned for chemotherapy were eligible for enrolment in the study. The primary endpoint of the study was the assessment of complete response (CR) rates.

Results Overall, 1,276 consecutive patients were screened for this study, while 738 patients fulfilling the eligibility criteria were included. A total of 23.2% of the whole cohort failed to achieve CR. Also, 28.2, 16.9, and 16.6% of patients receiving moderately emetogenic chemotherapy (MEC), low emetogenic chemotherapy (LEC), and high emetogenic chemotherapy (HEC), respectively, failed to achieve CR. The differences in failure to achieve CR was statistically significant between MEC and HEC (p < 0.001) groups. Among MEC group, there was no difference between those who received oxaliplatin (27.8%) versus nonoxaliplatin regimens (25.8%) in terms of failure rates (p = 0.613).

Conclusion Approximately one-fourth of patients failed to achieve a complete response from CINV in GI cancers despite using guideline-based AEP. Patients receiving MEC had the highest failure rates suggesting a need to improve AEP in these patients.

Keywords

CINV - moderately emetogenic chemotherapy - MEC - oxaliplatin - complete response

• References

• 1 Cohen L, de CA Moor, Eisenberg P, Ming EE, Hu H. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 2007; 15 (05) 497-503
• 2 Lachaine J, Yelle L, Kaizer L, Dufour A, Hopkins S, Deuson R. Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada. Support Cancer Ther 2005; 2 (03) 181-187
• 3 Roila F, Molassiotis A, Herrstedt J. et al. participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016; 27 (Suppl. 05) v119-v133
• 4 Hesketh PJ, Kris MG, Basch E. et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol 2017; 35 (28) 3240-3261
• 5 Vaid AK, Gupta S, Doval DC. et al. Expert consensus on effective management of chemotherapy-induced nausea and vomiting: an Indian perspective. Front Oncol 2020; 10: 400
• 6 Jain S, Engineer R, Ostwal V. et al. Addition of short course radiotherapy in newly diagnosed locally advanced rectal cancers with distant metastasis. Asia Pac J Clin Oncol. 2020
• 7 Chaudhary NK, John RR, Boddu D, Mahasampath G, Nesadeepam N, Mathew LG. Palonosetron is a better choice compared with ondansetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in a resource-limited pediatric oncology center: results from a randomized control trial. J Pediatr Hematol Oncol 2019; 41 (04) 294-297
• 8 Patil VM, Noronha V, Joshi A. et al. Adherence to and implementation of ASCO antiemetic guidelines in routine practice in a tertiary cancer center in India. J Oncol Pract 2017; 13 (06) e574-e581
• 9 Fujii H, Iihara H, Ishihara M, Takahashi T, Yoshida K, Itoh Y. Improvement of adherence to guidelines for antiemetic medication enhances emetic control in patients with colorectal cancer receiving chemotherapy of moderate emetic risk. Anticancer Res 2013; 33 (12) 5549-5556
• 10 Suzuki A, Kobayashi R, Fujii H. et al. Control of nausea and vomiting in patients with colorectal cancer receiving chemotherapy with moderate emetic risk. Anticancer Res 2016; 36 (12) 6527-6533
• 11 Nishimura J, Satoh T, Fukunaga M. et al. Multi-center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO). Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Eur J Cancer 2015; 51 (10) 1274-1282
• 12 Vaswani B, Bhagat S, Patil S, Barkate H. Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: a real-life study from India. World J Clin Oncol 2020; 11 (08) 606-613
• 13 Binder G, Saunders WB. Chemotherapy-induced nausea and vomiting (CINV) - incidence by age and sex among patients receiving oxaliplatin. International Society For Pharmacoeconomics and Outcomes Research 2018; 21 (Suppl. 01) S14
• 14 Iihara H, Ishihara M, Fujii H. et al. Comparison of the control of nausea and vomiting among several moderately emetic-risk chemotherapy regimens. J Cancer 2016; 7 (05) 569-575
• 15 Babu G, Saldanha SC, Kuntegowdanahalli Chinnagiriyappa L. et al. The efficacy, safety, and cost benefit of olanzapine versus aprepitant in highly emetogenic chemotherapy: a pilot study from South India. Chemother Res Pract 2016; 2016: 3439707